Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody with high affinity for PD-1 and has demonstrated antitumor activity in patients with ESCC and gastroesophageal junction adenocarcinoma, either alone or in combination with chemotherapy in clinical trials [12–15]. Here, PDCD1 is linked to gastroesophageal junction adenocarcinoma.